Overview

Price chart · mood · technical indicators

IONS

Ionis Pharmaceuticals Incstock Healthcare

Biotechnology

$73.28107.93%Current Market Mood:Neutral

Market Mood

Price Range (1Y)

$34.78$86.74

Current: $73.28

Idea: EMA

1Y Return

+76.0%

Sharpe 3Y

0.60

Market Comparison

vs Healthcare Sector & Biotechnology Industry

IONS

+107.93%

1Y Performance

Fundamentals

Updated daily after market close

P/E ratio—Forward 90.91

EPS (TTM)$-2.01-43.7% YoY

Profit margin-30.9%HEALTHCARE

Market cap$12.11BLarge cap

Wall Street coverage

$102.17median target· current $40.65 (+151.3%)26 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: 90.91
PEG ratio: 25.70
P/B: 24.64
P/S (TTM): 11.44
EV/EBITDA: 135.77

Profitability & growth

ROE (TTM): -67.6%
Operating margin: -47.7%
Revenue growth YoY: 87.0%
Dividend yield: —
Beta: 0.37

Last earnings

Apr 29, 2026 · Estimate $-0.77 · Reported $-0.30

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Ionis Pharmaceuticals Inc

Company profile

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapies in the United States. The company is headquartered in Carlsbad, California.

Classification

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 2855 GAZELLE COURT, CARLSBAD, CA
Fiscal year end: December
Latest quarter: Mar 31, 2026

Market cap$12.11B

Shares outstanding$165.3M

52W high$86.74

52W low$34.78

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer

Overview

IONS

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Olezarsen liver fat study data highlighted by Ionis (NASDAQ: IONS)

GSK, Ionis mark late-stage trial win for chronic hepatitis B therapy

Diabetic Retinopathy Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Genentech, Ionis Pharma, AstraZeneca, Regenxbio, AbbVie, Palatin Techn, Avirmax

Franklin Resources Inc. Has $104.53 Million Stake in Ionis Pharmaceuticals, Inc. $IONS

Norges Bank Invests $25.33 Million in Ionis Pharmaceuticals, Inc. $IONS

Ionis Pharmaceuticals Adds Veteran Leader to Board

Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors

Ionis Pharmaceuticals adds Ludwig Hantson to board By Investing.com

Ionis Pharmaceuticals adds Ludwig Hantson to board

Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors

Long term debt to total equity ratio of Ionis Pharmaceuticals, Inc. – XETR:ISI

Ionis Pharmaceuticals, Inc. Revenue Breakdown – XETR:ISI

Analyst Commentary Highlights Ionis Pharmaceuticals’ Upward Price Target and Valuation Amid Key Clinical Wins

ETFs Investing in Ionis Pharmaceuticals, Inc. Stocks

Debt to assets ratio of Ionis Pharmaceuticals, Inc. – XETR:ISI

Price to book ratio of Ionis Pharmaceuticals, Inc. – XETR:ISI

Ionis Pharmaceuticals Announces New Data on Olezarsen for sHTG Treatment

Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses

Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses

Pancreatitis risk data on olezarsen ahead of June 30 FDA action date

About Ionis Pharmaceuticals Inc

Classification

Company profile

IONS

Market Comparison

IONS Market Analysis

Overview

IONS

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Olezarsen liver fat study data highlighted by Ionis (NASDAQ: IONS)

GSK, Ionis mark late-stage trial win for chronic hepatitis B therapy

Diabetic Retinopathy Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Genentech, Ionis Pharma, AstraZeneca, Regenxbio, AbbVie, Palatin Techn, Avirmax

Franklin Resources Inc. Has $104.53 Million Stake in Ionis Pharmaceuticals, Inc. $IONS

Norges Bank Invests $25.33 Million in Ionis Pharmaceuticals, Inc. $IONS

Ionis Pharmaceuticals Adds Veteran Leader to Board

Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors

Ionis Pharmaceuticals adds Ludwig Hantson to board By Investing.com

Ionis Pharmaceuticals adds Ludwig Hantson to board

Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors

Long term debt to total equity ratio of Ionis Pharmaceuticals, Inc. – XETR:ISI

Ionis Pharmaceuticals, Inc. Revenue Breakdown – XETR:ISI

Analyst Commentary Highlights Ionis Pharmaceuticals’ Upward Price Target and Valuation Amid Key Clinical Wins

ETFs Investing in Ionis Pharmaceuticals, Inc. Stocks

Debt to assets ratio of Ionis Pharmaceuticals, Inc. – XETR:ISI

Price to book ratio of Ionis Pharmaceuticals, Inc. – XETR:ISI

Ionis Pharmaceuticals Announces New Data on Olezarsen for sHTG Treatment

Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses

Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses

Pancreatitis risk data on olezarsen ahead of June 30 FDA action date

About Ionis Pharmaceuticals Inc

Classification

Company profile

IONS

Market Comparison